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OBJECTIVES We sought to examine the implications of the timing of onset of cardiogenic shock (CS) after
acute myocardial infarction (MI).
BACKGROUND Little information is available about the relationships between timing, clinical substrate,
management and outcomes of shock.
METHODS The multinational SHOCK Trial Registry enrolled MI patients with CS from 1993 to 1997.
Cardiogenic shock was predominantly attributable to left ventricular (LV) failure in 815
Registry patients for whom temporal data were available. We examined factors related to the
timing of shock onset and the relation of temporal onset to in-hospital outcomes.
RESULTS Overall, shock developed a median of 6.2 h after MI symptom onset. Shock onset varied by
culprit artery: left main, median 1.7 h; right, 3.5 h; circumflex, 3.9 h; left anterior descending
(LAD), 11.0 h; saphenous vein graft, 10.9 h (p 5 0.025). Early shock (,24 h) occurred in
74.1% and was associated with chest pain at shock onset, ST-segment elevation in two or
more leads, multiple infarct locations, inferior MI, left main disease and smoking. Late shock
($24 h) was associated with recurrent ischemia, Q waves in two or more leads and LAD
culprit vessel. Mortality was higher in patients with early versus late shock (62.6% vs. 53.6%,
p 5 0.022).
CONCLUSIONS Shock onset after acute MI occurred within 24 h in 74% of the patients with predominant LV
failure. Mortality was slightly higher in patients developing shock early rather than later.
Many factors influence when shock develops, which has implications for its management.
(J Am Coll Cardiol 2000;36:1084 –90) © 2000 by the American College of Cardiology
Cardiogenic shock (CS) is the major cause of mortality
among patients hospitalized for acute myocardial infarction
(AMI) (1–4). Yet, most patients who develop shock are not
in shock when they first arrive at the hospital (1–3). Little
information is available with respect to the timing of shock
onset, and less is available about the relationships between
timing, clinical substrate, management and outcome. What
data are available are based on highly selected cohorts of
shock patients (3,5).
The SHould we emergently revascularize Occluded Cor-
onaries for cardiogenic shocK? (SHOCK) Trial Registry
was a prospective, multicenter registry of patients with
known or suspected CS complicating AMI. Using this
Registry, we sought to describe the temporal and clinical
patterns of shock onset due to predominant left ventricular
(LV) failure in a large and relatively unselected population.
METHODS
Patient sample. Thirty-six multinational centers prospec-
tively enrolled patients with suspected CS complicating
AMI into the SHOCK Trial Registry and the SHOCK
Trial from 1993 to 1997 and from 1993 to 1998, respec-
tively (6). Of the 1,190 patients enrolled in the Registry,
306 patients were excluded because shock was attributable
to mechanical causes, clinically diagnosed “isolated” right
ventricular (RV) infarction or factors other than predomi-
nant LV failure. A total of 884 patients (74%) were
classified with CS due to predominant LV failure, 69 of
whom were excluded from analysis because of inadequate
information about the timing of MI or shock onset. Data
were thus available on 815 patients with post-MI CS
primarily due to LV failure. This cohort constitutes the
basis of this report. Results from the 302 patients in the
concurrent randomized SHOCK Trial are reported for
comparison.
Data collection. Coordinators prospectively identified pa-
tients who had a clinical diagnosis of suspected CS compli-
cating MI. Local discharge diagnoses of AMI and of CS
(DRGs 410 combined with 785.51) constituted criteria for
being registered. Patients randomized in the SHOCK Trial
were excluded from the Registry (6,7). Data were abstracted
from the medical record by study coordinators who were
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centrally trained to complete standard report forms. Right-
heart catheterization was performed in 523 patients, the
pulmonary capillary wedge was recorded in 490, and the
cardiac index in 441. Left ventricular ejection fraction was
measured during hospitalization in 311 patients by LV
angiography (37%), by echocardiogram (59%) or by gated
blood-pool scan (5%). The following variables were on
revised data forms and were available for a maximum of 583
patients: ejection fraction, pulmonary-artery and RV pres-
sures, chest pain at shock onset, history of elevated lipids,
peripheral vascular disease, inotropic agent usage, and re-
infarction/recurrent ischemia.
Definitions. Three temporal groups were identified. Early
shock was defined as shock developing ,24 h after MI
onset. Late shock was defined as shock developing $24 h
after MI onset. A third group with very early shock was
identified, consisting of patients who developed shock ,6 h
after MI onset. The early (,24 h) versus late ($24 h)
groups were compared.
Predominant LV failure was considered to be the cause of
CS in the absence of isolated RV infarction, acute severe
mitral regurgitation, ventricular rupture, tamponade, severe
valvular disease, excess beta or calcium-channel blockade or
shock resulting from a complication of cardiac catheteriza-
tion. Re-infarction was defined as: 1) recurrent chest pain or
ischemic symptoms for $30 min with recurrent ST-
segment elevation, new Q waves, or new left bundle branch
block; 2) a total creatine kinase (CK) at least twice the upper
limit of normal and $25% or 200 U/mL over the previous
value, with an elevated CK-MB; or 3) increase in CK-MB
to above the upper limit of normal after a reversion to
normal. Recurrent ischemia was defined as rest angina or
ischemic symptoms for $5 min with ST-segment depres-
sion, T-wave inversion, or both, without cardiac enzyme
elevation.
Statistical analysis. Comparisons of the early and late
shock groups were conducted using the Fisher exact test for
unordered categorical variables, the Mantel-Haenszel test
for linear trend for ordered categorical variables (8), the
Wilcoxon rank-sum test for ordinal or non-normally dis-
tributed variables, and the Student t-test for all other
continuous variables. Logistic regression was used to deter-
mine whether early (vs. late) shock was an independent
predictor of mortality, adjusted for differences in patient and
treatment characteristics. All variables with a univariate p
value ,0.20 for early versus late shock were considered,
except for the use of inotropic agents and right heart
catheterization measurements (because of incomplete data).
Results with a p value ,0.05 were considered statistically
significant. Analyses were conducted using Statistical Anal-
ysis, version 6.12 (SAS Institute; Cary, North Carolina).
RESULTS
Timing of shock onset. Most patients presented to the
hospital early after the onset of MI. The median delay from
MI symptom onset to hospital admission was 1.25 h (25th
and 75th percentiles, 0.17 h and 4.17 h, respectively) and
from admission to shock onset, 4.6 h (25th and 75th
percentiles, 0.2 h and 28.4 h, respectively). The median time
from MI symptom onset to shock onset was 6.2 h (25th and
75th percentiles, 1.7 h and 20.1 h, respectively) in the
Registry; similar to the 5.5 h (25th and 75th percentiles,
2.3 h and 14.1 h, respectively) in the randomized SHOCK
Trial (p 5 0.103) (9). Very early shock (shock onset ,6 h
after MI onset) was identified in 46.6% of Registry patients,
early shock (onset ,24 h) in 74.1% and late shock (onset
$24 h) in 25.9%. Shock was diagnosed at presentation in
9% of the Registry patients and 14% of the Trial patients
(9).
Relationship between clinical characteristics and the
timing of shock onset. The demographic, historical, clin-
ical, hemodynamic and MI management characteristics of
the temporal groups were similar (Tables 1–3). Early shock
was more often associated with chest pain at shock onset,
ST-segment elevation in two or more leads, multiple loca-
tions of MI (by electrocardiogram [ECG]), inferior MI,
smoking, mechanical ventilation, hypotension, coronary
angiography and percutaneous transluminal coronary angio-
plasty (PTCA) after shock onset, and in-hospital death.
Late shock ($24 h) was more often associated with recur-
rent ischemia, the presence of new Q waves in two or more
leads, the use of inotropic agents and transfer to a tertiary
care center.
Recurrent ischemia. Chest pain was reported in 83.8% of
all patients and occurred at shock onset in 55.9% (Table 3).
Chest pain at the time of shock onset was more common
with early shock than with late shock (62.3% vs. 35.9%, p ,
0.0001). Recurrent ischemia after the initial MI and before
shock onset was more common in the late shock group (38%
vs. 13.2%, p , 0.0001). Re-infarction after the initial MI
and before shock onset was diagnosed in 8.3% of patients,
with no difference between temporal groups.
Angiographic findings. Coronary angiographic data are
presented in Table 4. Most patients had multivessel disease
(78%). Shock developed earlier after MI with left main
diameter stenosis $50% (median 5.9 h), single-vessel dis-
ease (5.5 h), or double-vessel disease (4.6 h), compared with
triple-vessel disease (7.8 h), but these differences were not
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CS 5 cardiogenic shock
CK-MB 5 creatine kinase (-MB fraction)
ECG 5 electrocardiogram, electrocardiographic
LAD 5 left anterior descending (artery)
LV 5 left ventricular, left ventricle
PTCA 5 percutaneous transluminal coronary
angioplasty
RV 5 right ventricular, right ventricle
SHOCK 5 SHould we emergently revascularize
Occluded Coronaries for cardiogenic shocK?
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significant. The distributions of the number of diseased
vessels did not differ significantly between the early- and
late-shock groups. Although the left anterior descending
(LAD) artery was the most common culprit vessel for both
groups for patients, late shock patients were even more
likely to have the LAD artery as the culprit (56%) than early
shock patients (40.6%), while the right coronary artery was
more often the culprit in early shock patients (30.3%),
compared with late shock patients (20%, p 5 0.025). The
median time to shock onset was shortest when the culprit
artery was the left main (1.7 h), shorter in the case of the
right coronary (3.5 h) or circumflex (3.9 h) and longest in
the case of the LAD (11 h) and saphenous vein grafts
(10.9 h). Over two thirds of the patients in both groups had
Thrombolysis In Myocardial Infarction flow grade 0/1 in
the culprit artery; vessel patency was not associated with
timing of shock (p 5 0.699).
Revascularization and mortality. Overall in-hospital mor-
tality was 60.3% (Table 5). Mortality was significantly
higher in patients with early shock versus late shock (62.6%
vs. 53.6%, p 5 0.022). This higher mortality with early
shock was most evident in the 58% of patients admitted
directly to a SHOCK Registry hospital (mortality 69.6% vs.
58.8%, p 5 0.043). Although the interaction of shock
timing and transfer status was not significant (p 5 0.288), a
survival advantage for late shock patients was not evident in
the 41% of patients selected for and surviving transfer to a
SHOCK Registry hospital (51.7% for early shock vs. 48.6%
for late shock, p 5 0.644). The in-hospital mortality rates
for patients with shock at presentation in the Registry and
Trial were similar (64.3% vs. 74.8%, p 5 0.178) (9).
Multivariate analysis was conducted to determine whether
timing of shock was an independent predictor of mortality after
adjustment for patient and treatment factors associated with
Table 1. Baseline Characteristics and Timing of Shock Due to Predominant LV Failure
Overall
(n 5 815)









Age (yrs) 68.6 6 12.0 67.9 6 12.1 68.2 6 12.2 69.6 6 11.4 0.135
Male gender 63.8% 65.3% 63.3% 65.4% 0.618
Transfer to tertiary care center 42.3% 35.8% 39.1% 51.7% 0.001
History of hypertension 51.9% 50.0% 52.4% 50.5% 0.688
Diabetes 32.2% 29.7% 32.2% 32.1% 1.000
History of congestive heart failure 19.5% 21.1% 19.9% 18.3% 0.683
Smoking 50.9% 53.5% 53.3% 44.6% 0.042
History of renal insufficiency 10.0% 8.0% 8.7% 13.5% 0.057
History of hyperlipidemia† 41.5% 40.7% 43.1% 37.6% 0.320
History of peripheral vascular
disease‡
18.6% 20.2% 18.2% 19.7% 0.698
History of infarction 40.2% 43.3% 41.1% 37.6% 0.407
History of angioplasty 6.7% 8.0% 7.2% 5.3% 0.420
History of bypass surgery 10.6% 10.8% 10.8% 10.0% 0.795
*p value for ,24 h vs. $24 h; †Hyperlipidemia data available for 407 patients; ‡peripheral vascular disease data available for 512
patients.
MI 5 myocardial infarction.













ST-segment elevation $2 leads 73.1% 76.6% 76.5% 63.3% 0.0003
New Q waves in $2 leads 32.7% 29.1% 30.6% 38.8% 0.032
Q waves with ST elevation 14.2% 14.1% 14.5% 13.3% 0.731
New left bundle-branch block 11.0% 12.1% 10.1% 13.3% 0.201
Location of infarction
Anterior 59.9% 53.9% 58.1% 65.4% 0.097
Inferior 43.4% 48.7% 46.0% 35.7% 0.016
Posterior 17.5% 17.7% 17.6% 17.0% 0.911
Lateral 31.5% 33.0% 32.9% 27.5% 0.198
Apical 9.8% 9.2% 10.2% 8.8% 0.668
Multiple locations 49.1% 49.7% 51.4% 42.3% 0.040
Highest creatine kinase, IU/L† 1,961 2,218 2,078 1,562 0.085
*p value for ,24 h vs. $24 h.
MI 5 myocardial infarction.
1086 Webb et al. JACC Vol. 36, No. 3, Suppl A
Timing of CS September 2000:1084–90
shock timing (transfer status, systolic blood pressure, revascu-
larization and ventilator use). This analysis did not support a
relationship between timing of shock post-MI and mortality
(late vs. early shock odds ratio for death 5 0.86, 95%
confidence interval, 0.59–1.25; p 5 0.430).
DISCUSSION
The timing of shock. According to retrospective studies
(2,5,6), from 1% of 5% of patients with AMI arrive at the
hospital in CS, while another 5% to 7% develop shock
during hospitalization. Our large, prospective, multicenter
study confirms that a small minority of patients (9%) were in
shock at arrival, while the majority developed shock after
presentation. Nevertheless, about half of our patients
(46.6%) who developed CS did so within 6 h of infarct
onset. This raises speculation that the diagnosis of severe
pump failure or pre-shock may be missed at presentation or
that early therapy, including use of agents that may induce













Time from MI to shock onset†
(median hours)
6.2 1.7 3.5 51.3 —
Chest pain at shock onset 55.9% 71.6% 62.3% 35.9% , 0.0001
Chest pain 83.8% 79.5% 83.1% 85.7% 0.447
Recurrent ischemia pre-shock
(n 5 580)
19.3% 9.7% 13.2% 38.0% , 0.0001
Reinfarction pre-shock
(n 5 581)
8.3% 9.0% 8.2% 8.3% 1.00
Systolic pressure (mm Hg) 87.8 6 23.0 85.9 6 25.6 86.7 6 23.7 91.3 6 20.6 0.014
Diastolic pressure (mm Hg) 52.5 6 17.3 51.3 6 19.6 51.6 6 18.0 54.9 6 14.7 0.031
Heart rate (per minute) 94.9 6 25.8 93.7 6 26.9 94.4 6 26.0 96.5 6 25.2 0.337
Right-heart catheterization 64.2% 60.3% 62.3% 69.7% 0.055
Cardiac index (L/min) 2.06 6 0.78 1.97 6 0.74 2.03 6 0.80 2.11 6 0.73 0.241
PCWP (mm Hg) 23.7 6 8.6 23.9 6 8.8 23.8 6 8.8 23.7 6 8.1 0.699
Left ventricular ejection fraction
(n 5 311)
30.4 6 12.5 32.6 6 13.7 30.6 6 12.7 29.9 6 11.9 0.647
Ventilator use 74.9% 79.5% 78.2% 65.4% 0.0003
Inotropic agents given 71.7% 65.1% 67.1% 85.4% , 0.0001
Intra-aortic balloon pump use 53.1% 56.6% 52.8% 54.0% 0.810
*p value for ,24 h vs. $24 h; †median values.
MI 5 myocardial infarction; PAWP 5 pulmonary capillary wedge pressure.
Hemodynamic values were obtained on support measures.





MI to Shock Onset
p
Value<6 h <24 h >24 h
Coronary angiography 61.1% 62.1% 59.8% 64.9% 0.191
Diseased vessels (n 5 474) (n 5 223) (n 5 342) (n 5 132) 0.584
0/1† 5.4 21.9% (104) 23.8% 19.3% 21.2%
2 4.6 20.0% (95) 22.9% 20.8% 18.2%
3 7.8 58.0% (275) 53.4% 57.0% 60.6%
Left main disease ($50%) 5.9 17.0% (79) 17.1% 16.5% 18.2% 0.682
No left main disease 6.8 83.1% (387) 83.0% 83.5% 81.8%
Culprit artery (n 5 381) (n 5 188) (n 5 281) (n 5 100) 0.025
Left anterior descending 11.0 44.6% (170) 36.7% 40.6% 56.0%
Circumflex 3.9 13.1% (50) 14.4% 12.8% 14.0%
Right 3.5 27.6% (105) 33.5% 30.3% 20.0%
Left main 1.7 6.6% (25) 9.0% 8.2% 2.0%
Saphenous vein graft 10.9 8.1% (31) 6.4% 8.2% 8.0%
TIMI flow grade (n 5 337) (n 5 169) (n 5 251) (n 5 86) 0.699
0 or 1 5.0 68.0% (229) 70.4% 67.3% 69.8%
2 6.0 19.0% (64) 18.3% 21.1% 12.8%
3 8.5 13.1% (44) 11.2% 11.6% 17.4%
Thrombolytic therapy 6.9 35.8% (291) 36.7% 38.2% 28.9% 0.016
No thrombolytic therapy 6.1 64.2% (522) 63.3% 61.8% 71.1%
*p value for ,24 h vs. $24 h, Mantel-Haenszel test for linear trend for number of diseased vessels and TIMI flow grade; Fisher exact test for all other variables. †3 patients
(2 early shock, 1 late shock) had no vessels with significant disease.
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hypotension, may cause iatrogenic shock in marginally
compensated patients (10). By 24 h, almost three quarters
(74.1%) of those who would eventually develop shock had
done so. By implication, then, there is often a therapeutic
window that could allow for intervention either before CS
develops or early in its course. The median time from
hospital admission to shock onset was only 4.6 h, however,
indicating that the window is relatively narrow for many
patients.
Early shock. It is intuitive to suspect that shock might
occur early after MI due to occlusion of a major coronary
artery and very extensive myocardial damage. Not surpris-
ingly, early shock was more often associated with ST-
segment elevation in multiple leads and with multiple ECG
infarct locations. The LAD coronary artery was the most
common culprit vessel regardless of the time of shock onset.
Nevertheless, patients in whom the right coronary artery
was the culprit, or who had inferior MI on clinical grounds,
were relatively more likely to develop shock early. Mortality
in these patients may be reduced with aggressive medical
support and reperfusion strategies (11–13). Although pa-
tients clinically diagnosed with “isolated” RV MI were
excluded from analysis, RV involvement may have been a
significant factor in many patients thought to suffer primar-
ily from LV involvement. Excessive vagal tone may play a
role in this setting by limiting the compensatory tachycar-
dia, inotropy and vasoconstriction otherwise associated with
myocardial dysfunction (11,12).
Late shock. More than 25% of patients who developed
shock did so relatively late ($24 h) after MI. With a median
delay of 51 h after MI onset in this group, the implications
for etiology and treatment may differ from those for patients
developing shock early (16). Several factors may favor the
delayed appearance of shock. Infarct expansion may pro-
gressively reduce mechanical efficiency, particularly after
large anterior MIs (3,13). This relationship may underlie
the frequent association between a culprit LAD artery,
multiple new Q waves and late shock.
Infarct extension may follow thrombotic reocclusion of a
temporarily patent infarct artery, propagation of intracoro-
nary thrombus, occlusion of a remote artery, reduced coro-
nary perfusion pressure or increased myocardial oxygen
demand. Shock patients are more likely to have persistently
elevated cardiac enzymes, myocardium in varying stages of
necrosis and clinical re-infarction, suggesting an important
role for ongoing or recurrent ischemia (3,4). The greater
incidence of recurrent ischemia in patients with late shock
suggests that measures that reduce recurrent ischemia also
may reduce the incidence of late shock.
In patients with multivessel disease, reduced systemic
arterial pressure may exacerbate ischemia that is remote
from the infarct region and compromise non–infarct zone
myocardial function (3,15). Metabolic derangements may
impair the contractility of non-infarcted myocardium
(3,14). Although most shock patients undergoing angiog-
raphy had an identifiable culprit artery (possibly amenable to
thrombolysis or PTCA), most also had multivessel disease
(77.5%), suggesting that more complete revascularization
(13,15) with multivessel PTCA or bypass surgery might be
desirable in the setting of late shock.
Mortality and timing of shock. Regardless of the time of
shock onset, mortality remains high. In-hospital mortality
was higher in patients presenting with early shock (,24 h)
versus late shock ($24 h) (62.6% vs. 53.6%). Almost half of
the patients admitted to SHOCK tertiary-care hospitals
were transferred from other institutions, and their mortality
was lower than that of patients admitted directly to tertiary
hospitals. This may reflect a selection bias, considering that
late shock patients had a higher transfer rate than early
shock patients: patients with a higher risk of early mortality
are excluded from the transferred cohort, and the patients
most likely to benefit from aggressive management may be
selected for transfer. The similar outcome seen with early
and late shock in transferred patients may reflect this
selection process. Among relatively unselected patients
(those admitted directly to a SHOCK Trial Registry hos-
Table 5. Revascularization and In-hospital Mortality in Relation to Timing of Shock Onset
Overall
(n 5 815)











49.3% 55.3% 51.4% 43.3% 0.045
Angioplasty (post-
shock)
27.7% 37.4% 31.0% 18.2% 0.0003
Bypass surgery (post-
shock)
15.6% 13.7% 14.6% 18.5% 0.186
Any revascularization
attempt
41.1% 48.7% 43.1% 35.4% 0.061
Angioplasty mortality 45.4% 55.9% 48.3% 35.6% 0.102
Bypass surgery
mortality
28.6% 18.9% 27.5% 31.0% 0.685
In-hospital mortality 60.3% 62.4% 62.6% 53.6% 0.022
*p value for ,24 h vs. $24 h.
MI 5 myocardial infarction.
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pital), a worse outcome with early shock was particularly
evident (mortality 69.6% vs. 58.8%). This relationship was
supported by multivariate analysis.
Reperfusion therapy in shock. Reperfusion therapy can
improve outcome in CS (3,9,13,16–21). Unfortunately,
thrombolysis results in relatively low rates of reperfusion in
patients in whom shock is already established (22,23). The
randomized SHOCK Trial found a significant reduction in
six-month mortality with revascularization, with a 20.1%
absolute reduction in six-month mortality in patients age
,75 years (9). The likelihood of sustained reperfusion is
higher with PTCA and may be improved further when
combined with stenting, intra-aortic balloon pumping and
newer antiplatelet regimens (13,21,26). It seems reasonable
to expect that early reperfusion would be the most beneficial
(13,25), but even late reperfusion may be desirable (3,
11–13,18–20,26–32). Although this is speculative, reperfu-
sion therapy with thrombolysis or PTCA may be particu-
larly desirable in patients with early shock, which more
often may reflect occlusion of a single major coronary artery
and ongoing infarction.
Study limitations. Information is lacking with regard to
patients who die before they can be admitted to a hospital or
who are not selected for transfer from referral hospitals.
Conclusions. Most patients who develop CS do so rela-
tively early after MI. Shock developed within 6 h in about
50%, and within 24 h in 75%, of those who eventually
developed shock during hospitalization. Mortality is slightly
higher in patients with early shock. A therapeutic window is
often present, allowing for intervention before CS develops
or early during its course. Many factors appear to influence
the timing of shock onset, which probably has implications
for its management.
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